KR102410733B1 - 헌팅틴 단백질을 영상화하기 위한 프로브 - Google Patents

헌팅틴 단백질을 영상화하기 위한 프로브 Download PDF

Info

Publication number
KR102410733B1
KR102410733B1 KR1020177007881A KR20177007881A KR102410733B1 KR 102410733 B1 KR102410733 B1 KR 102410733B1 KR 1020177007881 A KR1020177007881 A KR 1020177007881A KR 20177007881 A KR20177007881 A KR 20177007881A KR 102410733 B1 KR102410733 B1 KR 102410733B1
Authority
KR
South Korea
Prior art keywords
imidazo
pyridine
carbonitrile
methoxy
methylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177007881A
Other languages
English (en)
Korean (ko)
Other versions
KR20170047303A (ko
Inventor
셀리아 도밍게즈
존 휘트약
조나단 바드
알렉스 키셀료프
크리스토퍼 존 브라운
마이클 에드워드 프라임
피터 데이비드 존슨
다니엘 클락-프류
Original Assignee
씨에이치디아이 파운데이션, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨에이치디아이 파운데이션, 인코포레이티드 filed Critical 씨에이치디아이 파운데이션, 인코포레이티드
Publication of KR20170047303A publication Critical patent/KR20170047303A/ko
Application granted granted Critical
Publication of KR102410733B1 publication Critical patent/KR102410733B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020177007881A 2014-08-29 2015-08-28 헌팅틴 단백질을 영상화하기 위한 프로브 Active KR102410733B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043590P 2014-08-29 2014-08-29
US62/043,590 2014-08-29
PCT/US2015/047401 WO2016033440A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Publications (2)

Publication Number Publication Date
KR20170047303A KR20170047303A (ko) 2017-05-04
KR102410733B1 true KR102410733B1 (ko) 2022-06-20

Family

ID=55400645

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177007881A Active KR102410733B1 (ko) 2014-08-29 2015-08-28 헌팅틴 단백질을 영상화하기 위한 프로브

Country Status (20)

Country Link
US (2) US11104691B2 (enExample)
EP (1) EP3197277B1 (enExample)
JP (1) JP6754353B2 (enExample)
KR (1) KR102410733B1 (enExample)
CN (1) CN107105667B (enExample)
AU (2) AU2015308769A1 (enExample)
BR (1) BR112017004140B1 (enExample)
CA (1) CA2959533C (enExample)
DK (1) DK3197277T3 (enExample)
EA (1) EA039923B1 (enExample)
ES (1) ES2905095T3 (enExample)
HR (1) HRP20220001T1 (enExample)
HU (1) HUE057702T2 (enExample)
IL (1) IL250802B (enExample)
MX (1) MX386798B (enExample)
PL (1) PL3197277T3 (enExample)
PT (1) PT3197277T (enExample)
SG (1) SG11201701592SA (enExample)
SI (1) SI3197277T1 (enExample)
WO (1) WO2016033440A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211778T1 (hr) 2014-08-29 2022-03-18 Chdi Foundation, Inc. Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina
SG11201701578YA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
SG11201701580XA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
PL3197277T3 (pl) 2014-08-29 2022-04-04 Chdi Foundation, Inc. Sondy do obrazowania molekularnego białka huntingtyny
CA2995847C (en) 2015-08-28 2024-05-28 Chdi Foundation, Inc. Probes for imaging huntingtin protein
AU2018346962A1 (en) * 2017-10-12 2020-05-28 BCN Biosciences L.L.C. Methods of treating radiation induced gastrointestinal syndrome
WO2020176424A1 (en) 2019-02-25 2020-09-03 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
CA3138873C (en) 2019-05-09 2024-01-09 Kyle Bradley Pascual CLAGG Synthesis of labeled imidazo[1,2-a]pyrimidines
CN114773312B (zh) * 2021-10-29 2024-03-26 北京鑫诺康桥药物研究有限公司 一种盐酸阿罗洛尔中间体的制备工艺
WO2026064501A1 (en) * 2024-09-18 2026-03-26 The University Of Chicago Reversible and irreversible kinome probes and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110065727A1 (en) 2008-03-21 2011-03-17 Sanofi-Aventis POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF
US20110171739A1 (en) 2008-09-23 2011-07-14 Wista Laboratories Ltd. Ligands for aggregated tau molecules
WO2015044095A1 (en) 2013-09-26 2015-04-02 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pyridin-7-amines as imaging tools

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10050663A1 (de) * 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
EP1655287A1 (en) * 2003-08-13 2006-05-10 BF Research Institute, Inc. Probe for diseases with amyloid accumulation, amyloid-staining agent, remedy and preventive for diseases with amyloid accumulation and diagnostic probe and staining agent for neurofibrillary change
CN101501033B (zh) * 2006-06-21 2012-08-01 通用电气医疗有限公司 对淀粉状蛋白具有亲和性的化合物
WO2008016648A2 (en) * 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
WO2008059714A1 (en) * 2006-11-17 2008-05-22 Nihon Medi-Physics Co., Ltd. Novel compounds with affinity for amyloid
CN101595108A (zh) * 2006-11-30 2009-12-02 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的新化合物
AU2008208091A1 (en) * 2007-01-22 2008-07-31 Astrazeneca Ab Novel heteroaryl substituted imidazo [1,2 -a] pyridine derivatives
JPWO2009057577A1 (ja) * 2007-10-30 2011-03-10 日本メジフィジックス株式会社 新規アミロイド親和性化合物の使用及び製造方法
WO2010011964A2 (en) * 2008-07-24 2010-01-28 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying ad pathology
WO2010141805A1 (en) * 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of trpa1
KR20140040722A (ko) * 2011-05-20 2014-04-03 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물
IN2014DN00185A (enExample) * 2011-06-24 2015-07-10 Nihon Mediphysics Co Ltd
JP2013237655A (ja) * 2012-05-17 2013-11-28 Kyoto Univ コンフォメーション病診断用分子プローブ
CN105209461A (zh) * 2012-11-14 2015-12-30 霍夫曼-拉罗奇有限公司 咪唑并吡啶衍生物
WO2014139882A1 (en) 2013-03-14 2014-09-18 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
SG11201701580XA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
PL3197277T3 (pl) 2014-08-29 2022-04-04 Chdi Foundation, Inc. Sondy do obrazowania molekularnego białka huntingtyny
HRP20211778T1 (hr) 2014-08-29 2022-03-18 Chdi Foundation, Inc. Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina
SG11201701578YA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
CA2995847C (en) 2015-08-28 2024-05-28 Chdi Foundation, Inc. Probes for imaging huntingtin protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110065727A1 (en) 2008-03-21 2011-03-17 Sanofi-Aventis POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF
US20110171739A1 (en) 2008-09-23 2011-07-14 Wista Laboratories Ltd. Ligands for aggregated tau molecules
WO2015044095A1 (en) 2013-09-26 2015-04-02 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pyridin-7-amines as imaging tools

Also Published As

Publication number Publication date
HUE057702T2 (hu) 2022-05-28
CA2959533A1 (en) 2016-03-03
US11104691B2 (en) 2021-08-31
EA039923B1 (ru) 2022-03-28
BR112017004140B1 (pt) 2023-01-10
PT3197277T (pt) 2022-02-01
EP3197277A4 (en) 2018-04-18
IL250802B (en) 2020-08-31
AU2019283999B2 (en) 2021-07-22
AU2019283999A1 (en) 2020-01-23
WO2016033440A1 (en) 2016-03-03
SG11201701592SA (en) 2017-03-30
DK3197277T3 (da) 2022-01-31
ES2905095T3 (es) 2022-04-07
MX386798B (es) 2025-03-19
US20210380608A1 (en) 2021-12-09
PL3197277T3 (pl) 2022-04-04
EA201790400A1 (ru) 2017-09-29
AU2015308769A1 (en) 2017-03-23
IL250802A0 (en) 2017-04-30
CN107105667B (zh) 2021-08-17
CN107105667A (zh) 2017-08-29
JP2017529340A (ja) 2017-10-05
EP3197277A1 (en) 2017-08-02
HRP20220001T1 (hr) 2022-04-01
US11851446B2 (en) 2023-12-26
MX2017002702A (es) 2017-10-23
EP3197277B1 (en) 2021-12-22
US20170283439A1 (en) 2017-10-05
JP6754353B2 (ja) 2020-09-09
CA2959533C (en) 2023-03-07
SI3197277T1 (sl) 2022-04-29
KR20170047303A (ko) 2017-05-04
BR112017004140A2 (pt) 2017-12-12

Similar Documents

Publication Publication Date Title
US12258355B2 (en) Probes for imaging huntingtin protein
US11851446B2 (en) Probes for imaging Huntingtin protein
KR102410760B1 (ko) 헌팅틴 단백질을 영상화하기 위한 프로브
US11344637B2 (en) Probes for imaging huntingtin protein
EP3190888B1 (en) Probes for imaging huntingtin protein
HK40110855A (en) Probes for imaging huntingtin protein
HK1241224B (en) Probes for imaging huntingtin protein
HK1241223A1 (en) Probes for imaging huntingtin protein
HK1241223B (en) Probes for imaging huntingtin protein
HK1257113B (en) Probes for imaging huntingtin protein
HK1257113A1 (en) Probes for imaging huntingtin protein

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4